Suggested remit - To appraise the clinical and cost effectiveness of galcanezumab within its marketing authorisation for preventing cluster headache.
Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1212

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
16 November 2022 Discontinued. Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
24 February 2021 Expected publication
17 April 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Galcanezumab for preventing episodic cluster headache. However, the company have advised that The European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for galcanezumab injection for the preventive treatment of episodic cluster headache in adults in the European Union. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
17 April 2020 Suspended. Topic is suspended
12 December 2019 In progress. Referred: April 29 2019
12 December 2019 Following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early April 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
13 November 2018 - 11 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual